Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Antimetabolites. Found 19 abstracts

Sato T, Issa JJ, Kropf P. DNA Hypomethylating Drugs in Cancer Therapy. Cold Spring Harbor perspectives in medicine. 2017 May;7(5).   PMCID: PMC5411681
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Talamonti MS, Small W, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology 13 (2): 150-158 Feb 2006. 2006 Feb;13(2):150-8.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002 Jun;62(11):3144-50.
Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ. Phase I and pharmacokinetic study of once daily oral administration of s-1 in patients with advanced cancer. Clin Cancer Res. 2002 Jul;8(7):2116-22.
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. The Journal of biological chemistry. 2001 Sep 07;276(36):33747-54.
Guo P, Ma J, Li S, Guo Z, Adams AL, Gallo JM. Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model. Cancer Chemother Pharmacol. 2001 Aug;48(2):169-76.
Meropol NJ, Niedzwiecki D, Hollis D, Schilsky RL, Mayer RJ. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. Cancer. 2001 Apr;91(7):1256-63.
Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001 Mar;5(2):121-30.
Willett C, Ajani J, Kelsen D, Sigurdson E, Abrams R, Berkey B, Benetz M, Crane C, Gaspar L, Goodyear MD, Gunderson L, Haddock M, Hoffmann J, Janjan N, John M, Kachnic L, Krieg R, Landry J, Meropol N, Minsky B, Mitchell E, Mohiuddin M, Moulder J, Myerson R, Noyes D, Pajak TF, Raben D, Regine W, Rich T, Robertson JM, Russell A, Skibber J, Kim P. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001 Jan;51(3 Suppl 2):19-27.
Held-Warmkessel J. Methotrexate. Clinical journal of oncology nursing. 2000 Jul;4(4):187-8.
Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. Journal of the National Cancer Institute. 2000 Dec 06;92(23):1934-40.
Lewis NL, Meropol NJ. Oral fluoropyrimidines in cancer treatment. Cancer Invest. 2000 Jan;18(8):747-60.
Ozols RF. The role of gemcitabine in the treatment of ovarian cancer. Semin Oncol. 2000 Feb;27(1 Suppl 2):40-7.
Schilder RJ, Blessing JA, Morgan M, Mangan CE, Rader JS. Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group. Gynecol Oncol. 2000 Feb;76(2):204-7.
Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol. 2000 Jul;18(14):2780-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Antimetabolites

Antineoplastic Antimetabolites Human drug therapy Female therapeutic use Deoxycytidine Male analogs & derivatives US Gov't Support-PHS Non-US Gov't Support administration & dosage Aged Adult metabolism Fluorouracil 80 and over Aged Middle Age Antineoplastic Combined Chemotherapy Protocols Animal pharmacokinetics Neoplasms pathology adverse effects analogs & derivatives mortality pharmacology Middle Aged Antineoplastic Agents Treatment Outcome Cisplatin surgery Carrier Proteins Adjuvant Radiotherapy Oral Administration genetics Survival Rate Transfection radiotherapy Methotrexate Adjuvant Chemotherapy chemically induced Multiple Drug Resistance Ovarian Neoplasms Squamous Cell Carcinoma use Mice Antineoplastic) 0 (Antimetabolites Pancreatic Neoplasms Uracil Lung Neoplasms dt [Drug Therapy] tu [Therapeutic Use] 951-77-9 (Deoxycytidine) Baculoviridae Biological Models therapy Head and Neck Neoplasms Maximum Tolerated Dose Comparative Study drug effects 103882-84-4 (gemcitabine) 3T3 Cells therapeutic adverse Survival Analysis methods Insects Enzyme Inhibitors effects Drug Monitoring Osmosis Prognosis Phytogenic Antineoplastic Agents blood Time Factors Immunoblotting Colorectal Neoplasms Drug Administration Schedule aa [Analogs & Derivatives] Anion Transport Proteins Local Neoplasm Recurrence immunology Tegafur Pyridines Clinical Trials Immunohistochemistry Kinetics ai [Antagonists & Inhibitors] Taxoids Gastrointestinal Diseases dosage Safety Metabolic Clearance Rate Drug Interactions Swine Acrylates DNA Demethylation Sprague-Dawley Rats Multidrug Resistance-Associated Proteins Radiation Oncology Anthracycline Antibiotics cytology Cultured Cells Estradiol Phosphorylation Radiotherapy Dosage Brain Neoplasms Adenocarcinoma ge [Genetics] Polymers Cell Survival Kidney Failure Retrospective Studies ad [Administration & Dosage] Cultured Tumor Cells Neoplasm Drug Resistance Bilirubin Drug Combinations Patient Education 7689-03-4 (Camptothecin) North America 6-Mercaptopurine Ribonucleotide Reductases Stomach Neoplasms Thiazoles Neoplasm DNA Liposomes Neutropenia ch [Chemistry] Isoquinolines diagnosis 0 (Antineoplastic Combined Chemotherapy Protocols) physiology organization & administration Drug Dose-Response Relationship Oncologic Nursing Patient Selection Gastrointestinal Neoplasms chemistry Conformal Radiotherapy Pancreaticoduodenectomy Forecasting Decitabine Biological Tumor Markers Disease-Free Survival Liver Diseases Cell Membrane 0 (Antineoplastic Agents) Etoposide
Last updated on Wednesday, August 12, 2020